Copyright © 2000 by the European Society of Cardiology.
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study
a Division of Cardiology, San Filippo Neri Hospital, Rome, Italy
b Division of Cardiology, Santissima Annunziata Hospital, Cento, Italy
c Cardiology Service—ICU, Policlinico Casilino, Rome, Italy
d Division of Cardiology, General Hospital, Asti, Italy
revised December 6, 1999; accepted December 18, 1999
Abstract
Aims This study compared the efficacy and safety of intravenous dofetilide with amiodarone and placebo in converting atrial fibrillation or flutter to sinus rhythm.
Methods and Results One hundred and fifty patients with atrial fibrillation or flutter (duration range 2h–6 months) were given 15-min intravenous infusions of 8µg.kg–1of dofetilide (n=48), 5mg.kg–1of amiodarone (n=50), or placebo (n=52) and monitored continuously for 3h. Sinus rhythm was restored in 35%, 4%, and 4% of patients, respectively (P<0·001, dofetilide vs placebo;P=ns, amiodarone versus placebo). Dofetilide was more effective in atrial flutter than in atrial fibrillation (cardioversion rates 75% and 22%, respectively;P=0·004). The mean time to conversion with dofetilide was 55±15min. Dofetilide prolonged the QTc interval (+16% at 20min). Amiodarone substantially decreased the ventricular rate in non-converters (–18beats.min–1at 30min). Two patients given dofetilide (4%) had non-sustained ventricular tachycardias, and four (8%) had torsade de pointes, in one case requiring electrical cardioversion.
Conclusion Intravenous dofetilide is significantly more effective than amiodarone or placebo in restoring sinus rhythm in patients with atrial fibrillation or flutter. However, when infused intravenously at this dose and rate, dofetilide causes a significant incidence of torsade de pointes.
Key Words: dofetilide, amiodarone, antiarrhythmic drugs, atrial fibrillation, atrial flutter, cardioversion
f1 Correspondence: Dr Leopoldo Bianconi, Via San Sotero 12, 00165 Rome, Italy. Email:kofler@opbg.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Shamiss, Y. Khaykin, R. Oosthuizen, D. Tunney, B. Sarak, M. Beardsall, C. Seabrook, L. Frost, Z. Wulffhart, B. Tsang, et al. Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation Europace, November 1, 2009; 11(11): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Geller, K. Egstrup, P. Kulakowski, M. Rosenqvist, M. A. Jansson, A. Berggren, N. Edvardsson, P. Sager, and H. J. Crijns Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009 J. Clin. Pharmacol., March 1, 2009; 49(3): 312 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roy, C. M. Pratt, C. Torp-Pedersen, D. G. Wyse, E. Toft, S. Juul-Moller, T. Nielsen, S. L. Rasmussen, I. G. Stiell, B. Coutu, et al. Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial Circulation, March 25, 2008; 117(12): 1518 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vassallo and R. G. Trohman Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications JAMA, September 19, 2007; 298(11): 1312 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The International Liaison Committee on Resuscitati The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support Pediatrics, May 1, 2006; 117(5): e955 - e977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Part 6: Pediatric Basic and Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roy, B. H. Rowe, I. G. Stiell, B. Coutu, J. H. Ip, D. Phaneuf, J. Lee, H. Vidaillet, G. Dickinson, S. Grant, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2355 - 2361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Letelier, K. Udol, J. Ena, B. Weaver, and G. H. Guyatt Effectiveness of Amiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm: A Meta-analysis Arch Intern Med, April 14, 2003; 163(7): 777 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chevalier, A. Durand-Dubief, H. Burri, M. Cucherat, G. Kirkorian, and P. Touboul Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis J. Am. Coll. Cardiol., January 15, 2003; 41(2): 255 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Nichol, F McAlister, B Pham, A Laupacis, B Shea, M Green, A Tang, and G Wells Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Heart, June 1, 2002; 87(6): 535 - 543. [Abstract] [Full Text] [PDF]
|
|